Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Baylor College of Medicine
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Stanford University
Baylor College of Medicine
Baylor College of Medicine
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Chicago
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Baylor College of Medicine
Fate Therapeutics
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Stanford University
Massachusetts General Hospital
University of California, San Francisco
Fred Hutchinson Cancer Center
TILT Biotherapeutics Ltd.
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Ossium Health, Inc.
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Francisco
H. Lee Moffitt Cancer Center and Research Institute
Baylor College of Medicine
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
Case Comprehensive Cancer Center
Sun Yat-sen University
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Fate Therapeutics
UNC Lineberger Comprehensive Cancer Center